Your Article Summary
See Latest ArticlesGolimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor-alpha inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial
The Lancet - Early Online Publication, 07/01/09
Smolen JS et al. – Phase III study reports that golimumab (TNFα inhibitor) reduced the signs and symptoms of rheumatoid arthritis in patients with active disease who had previously received one or more TNFα inhibitors.
Methods- Aim was to assess the efficacy and safety of the golimumab in pts with active RA who had previously received one or more TNFα inhibitors
- 461 pts, randomly allocated to receive sc injections of placebo (n=155), 50 mg golimumab (n=153), or 100 mg golimumab (n=153) every 4 wks between Feb 21, 2006, and Sept 26, 2007
- Eligible pts had been treated with at least one dose of a TNFα inhibitor previously
- Pts continued stable doses of MTX, sulfasalazine, hydroxychloroquine, oral corticosteroids, and NSAIDs
- Primary endpoint: achievement at wk 14 of ACR20
- At wk 16, pts who had <20% improvement in tender and swollen joint counts were given rescue therapy:
- changed treatment from placebo to 50 mg golimumab, or
- from 50 mg to 100 mg golimumab
- Drug efficacy was assessed by intention to treat and safety was assessed according to the study drug given
- Pts had discontinued previous TNFα inhibitors because of lack of effectiveness or intolerance and accessibility issues
- Pts had active disease, which was indicated by swollen and tender joints for the whole group
- 18% pts on placebo, 35% pts on 50 mg golimumab and 38% pts on 100 mg golimumab achieved ACR20 at wk 14
- 2 pts were never treated, and 57 pts did not complete the study because of AEs, unsatisfactory treatment effect, loss to f/u, death, or other reasons
- 155 pts on placebo, 153 on 50 mg golimumab, and 153 on 100 mg golimumab were assessed for drug efficacy
- For wks 1-16, serious AEs were recorded in 7% pts on placebo, 5% on 50 mg golimumab, and 3% on 100 mg golimumab
- For wks 1-24, after some pts were given rescue therapy, serious AEs were recorded in 10% pts on placebo, 5% on 50 mg golimumab, and 4% on 100 mg golimumab
Related Articles
Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial
Clinical Therapeutics, 10/15/09
Relevance Score: 71%
Certolizumab Pegol: In Rheumatoid Arthritis
BioDrugs, 11/11/09
Relevance Score: 70%
Assistive technology for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 70%
Treatment of early RA with infliximab is beneficial
American Pharmacists Association, 11/06/09
Relevance Score: 69%
Abatacept for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 69%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Late response to anti-TNF-alpha therapy in refractory mucocutaneous lesions of Behcets disease
Rheumatology International, 12/17/09
Unresponsiveness to Colchicine Therapy in Patients with Familial Mediterranean Fever Homozygous for the M694V Mutation
Journal of Rheumatology, 12/17/09
Can tumor necrosis factor inhibitors be safely used in pregnancy?
Journal of Rheumatology, 12/17/09
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study
Arthritis Research & Therapy, 12/17/09
First-line DMARD choice in early rheumatoid arthritis - Do prognostic factors play a role?
Rheumatology, 12/15/09
Klinefelters syndrome and rheumatoid arthritis: report of a case and review of the literature
International Journal of Rheumatic Diseases, 12/15/09